CClinicalTrials.gg
Sign In
RecruitingNCT02417740Updated Sep 22, 2026

Natural History of Noncirrhotic Portal Hypertension

An observational study in Cystic Fibrosis, Immunologic Deficiency Syndrome and Turner Syndrome, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruiting at 1 site in United States. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
12 Years to 100 Years
Sex
All
01

Study summary

Background:

- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.

Objectives:

- To learn more about how NCPH develops over time.

Eligibility:

- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.

Design:

  • Participants will have 2 screening visits.
  • Visit 1: to see if they have or may develop NCPH.
  • Medical history
  • Physical exam
  • Urine and stool studies
  • Abdominal ultrasound
  • Fibroscan. Sound waves measure liver stiffness.

\<TAB>- Visit 2:

  • Blood tests
  • Abdominal MRI
  • Echocardiogram
  • Questionnaire
  • Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.
  • They may have a liver biopsy.
  • All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.
  • Participants with NCPH will also have:
  • Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.
  • At least every 2 years: Esophagogastroduodenoscopy.
  • At least every 4 years: testing including HVPG measurements and liver biopsy.
  • Participants without NCPH will also have:
  • Liver biopsy and HVPG measurements to see if they have NCPH.
  • Every 2 years: abdominal MRI and stool studies.
  • The study will last indefinitely.
Read the detailed description

Study Description:

Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their

underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion

in the study.

Objectives:

Primary Objective:

1. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our

findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and

enhance transplant decision.

Secondary Objectives:

  1. Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting.
  2. Identification of the genetic modifiers of NCPH.
  3. Evaluation of hepatic transcriptome in absence and presence of NCPH.
  4. Characterization of microbiome signatures in NCPH.

Endpoints:

Primary Endpoints:

  1. Establish surveillance methods and guidelines for evaluation of NCPH.
  2. Develop an understanding of the biological mechanisms of the progression of NCPH.
  3. Identification of novel biomarkers correlating with NCPH progression.

Secondary Endpoints:

  1. Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity.
  2. Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype.
  3. Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis.
  4. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.
02

Conditions studied

  • Cystic Fibrosis
  • Immunologic Deficiency Syndrome
  • Turner Syndrome
  • Congenital Hepatic Fibrosis
  • Idiopathic Non-Cirrhotic Portal Hypertension

Keywords

  • Portal Hypertension
  • Portal Fibrosis
  • Liver Disease
  • Varices
  • Splenomegaly
  • Natural History
03

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with diagnosis of noncirrhotic portal hypertension above age of 12 years

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Male or female, aged >= 18 years of age, and minors 12-17 years of age.
  • Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.
  • Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Pregnancy.
  • Evidence of other forms of liver disease that typically result in cirrhosis.
  • Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL).
  • Hepatitis C as defined by the presence of hepatitis C RNA in serum.
  • Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
  • Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis.
  • Bile duct obstruction as suggested by imaging studies done within the previous six months.
  • The presence of cirrhosis confirmed by liver biopsy.
  • Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).
  • Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal \<6.6ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
  • Evidence of cholangiocarcinoma as suggested by liver histology.
  • Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
  • Inability to comply or give written informed consent.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)

Groups and cohorts

  • Adult with absence of Portal Hypertension

    Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.

  • Adult with presence of Portal Hypertension

    Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG \>5mmHg).

  • Minors likely to have the absence of Portal Hypertension

    Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.

  • Minors likely to have the presence of Portal Hypertension

    Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG \>5).

05

What researchers measure

Primary outcomes

  1. To study the natural history of non cirrhotic portal hypertension. It is an ongoing study.

    natural history study

    Time frame: Ongoing

06

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    • Jaha Norman-Wheeler · Contact · jaha.norman-wheeler@nih.gov · 301-435-6122
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contact · ccopr@nih.gov · (800) 411-1222
    Recruiting
07

References and documents

Publications

  • Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion. 1998 Jul-Aug;59(4):420-3. doi: 10.1159/000007502. No abstract available. PubMed 9693222 ↗
  • Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Lesmana LA, Guha Mazumder D, Omata M, Qureshi H, Raza RM, Sahni P, Sakhuja P, Salih M, Santra A, Sharma BC, Sharma P, Shiha G, Sollano J; Members of the APASL Working Party on Portal Hypertension. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007 Sep;1(3):398-413. doi: 10.1007/s12072-007-9010-9. Epub 2007 Sep 11. PubMed 19669336 ↗
  • Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011 Sep 2;54(3):1071-81. doi: 10.1002/hep.24422. Epub 2011 Jul 21. PubMed 21574171 ↗

Individual participant data

Plan to share: Undecided — This is a longitudinal study and it is not yet known if and when IPD will be made available.

08

Registry details

Key details

Study ID
NCT02417740
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
Jul 27, 2015
Primary completion
Sep 4, 2029 (estimated)
Completion
Sep 4, 2029 (estimated)
Last update
Sep 22, 2026

Study contacts

Jaha F Norman-Wheeler
Contact
jaha.norman-wheeler@nih.gov
(301) 435-6122
Theo Heller, M.D.
Contact
theoh@intra.niddk.nih.gov
(301) 402-7147
Theo Heller, M.D.
principal investigator · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cystic Fibrosis→

Other studies from this sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Start the discussion